NME3 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q13232 |
---|---|
Clone Names | 4012306 |
Gene ID | 4832 |
---|---|
Other Names | Nucleoside diphosphate kinase 3, NDK 3, NDP kinase 3, DR-nm23, Nucleoside diphosphate kinase C, NDPKC, nm23-H3, NME3 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP7156a was selected from the Center region of human NME3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | NME3 (HGNC:7851) |
---|---|
Function | Catalyzes the phosphorylation of ribonucleosides and deoxyribonucleoside diphosphates, other than ATP, into the corresponding triphosphates with ATP as the major phosphate donor (PubMed:11277919, PubMed:30587587). The ATP gamma phosphate is transferred to the nucleoside diphosphate beta phosphate via a ping- pong mechanism, using a phosphorylated active-site intermediate. Through the catalyzed exchange of gamma-phosphate between di- and triphosphonucleosides participates in regulation of intracellular nucleotide homeostasis (PubMed:11277919, PubMed:30587587). Inhibits granulocyte differentiation (PubMed:7638209). May be required for ciliary function during renal development (By similarity). |
Cellular Location | Mitochondrion outer membrane; Peripheral membrane protein. Cytoplasm Cytoplasm, cytoskeleton, cilium basal body {ECO:0000250|UniProtKB:Q9WV85} |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
NME3 mRNA is preferentially expressed at early stages of myeloid differentiation of highly purified CD34(+) cells. Its constitutive expression in a myeloid precursor line, which is growth-factor dependent for both proliferation and differentiation, results in inhibition of granulocytic differentiation induced by granulocyte colony-stimulating factor and causes apoptotic cell death. These results appear consistent with a role for the NME3 gene in normal hematopoiesis and raise the possibility that its overexpression contributes to differentiation arrest, a feature of blastic transformation in chronic myelogenous leukemia.
References
Negroni, A., et al., Cell Death Differ. 7(9):843-850 (2000).Martinez, R., et al., Cancer Res. 57(6):1180-1187 (1997).Venturelli, D., et al., Proc. Natl. Acad. Sci. U.S.A. 92(16):7435-7439 (1995).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.